Article Information
PubMed
History
- Received February 4, 2021
- Accepted January 18, 2021
- Published online February 21, 2021.
Article Versions
- Latest version (February 4, 2021 - 06:00).
- You are viewing the most recent version of this article.
Copyright & Usage
© 2021 Joule Inc. or its licensors This is an Open Access article distributed in accordance with the terms of the Creative Commons Attribution (CC BY-NC-ND 4.0) licence, which permits use, distribution and reproduction in any medium, provided that the original publication is properly cited, the use is noncommercial (i.e., research or educational use), and no modifications or adaptations are made. See: https://creativecommons.org/licenses/by-nc-nd/4.0/
Author Information
- Leena Taji, MPH,
- Doneal Thomas, MSc,
- Matthew J. Oliver, MD,
- Jane Ip, BASc,
- Yiwen Tang, MSc,
- Angie Yeung, BSc MBA,
- Rebecca Cooper, BA LLB,
- Andrew A. House, MD,
- Phil McFarlane, MD,
- Peter G. Blake, MSc MB
- Ontario Renal Network (Taji, Thomas, Oliver, Ip, Tang, Yeung, Cooper, McFarlane, Blake), Ontario Health; Department of Medicine (Oliver), University of Toronto, Toronto, Ont.; Schulich School of Medicine and Dentistry (House, Blake), Western University, London, Ont.; St. Michael’s Hospital (McFarlane), Toronto, Ont.
- Correspondence to: Peter Blake, peter.blake{at}lhsc.on.ca
Cited By...
In this issue
Article tools
COVID-19 in patients undergoing long-term dialysis in Ontario
Jump to section
Related Articles
Cited By...
- COVID-19 among Adults Receiving Home versus In-Center Dialysis
- Prioritizing Peritoneal Catheter Placement during the COVID-19 Pandemic: A Perspective of the American Society of Nephrology COVID-19 Home Dialysis Subcommittee
- Humoral Response to the Pfizer BNT162b2 Vaccine in Patients Undergoing Maintenance Hemodialysis
- Short-term antibody response after 1 dose of BNT162b2 vaccine in patients receiving hemodialysis
- The Humoral Response to the BNT162b2 Vaccine in Hemodialysis Patients
- Short-term antibody response and tolerability after one dose of BNT162b2 vaccine in patients receiving hemodialysis: A report from the Quebec Renal Network COVID-19 study
More in this TOC Section
Similar Articles
Collections
Podcast